NCT06600529 Combined Photo-Biomodulation At Acupuncture Points, Autologous PRP, and Umbilical Cord-Derived Exosome Therapy in Autism Spectrum Disorder
| NCT ID | NCT06600529 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Iffat Anwar Medical Complex |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-08-13 |
| Primary Completion | 2025-06-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2024-08-13 with a primary completion date of 2025-06-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to evaluate the efficacy of a combination of photo-biomodulation at acupuncture points, autologous platelet-rich plasma (PRP), and umbilical cord-derived exosome therapy in children with Autism Spectrum Disorder (ASD). The study will compare these interventions against standard care to determine their impact on the severity of autism symptoms, as measured by the Childhood Autism Rating Scale (CARS) and other related markers.
Eligibility Criteria
Inclusion Criteria: * • Diagnosis of Autism Spectrum Disorder based on DSM-5 criteria * Age 3-12 years * Stable on current medications for at least 4 weeks prior to study entry * Parents or legal guardians willing to provide informed consent Exclusion Criteria: * • Severe comorbid medical conditions * Prior stem cell or exosome therapy * History of hypersensitivity to any component of the interventions * Inability to comply with study procedures
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06600529 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 12 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06600529 currently recruiting?
Yes, NCT06600529 is actively recruiting participants. Contact the research team at shahzadtirmzi@yahoo.com for enrollment information.
Where is the NCT06600529 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT06600529 clinical trial?
NCT06600529 is sponsored by Iffat Anwar Medical Complex. The trial plans to enroll 100 participants.